Corindus Vascular Robotics Inc. has received 510(k) clearance from the FDA for its CorPath GRX Vascular Robotic System for Percutaneous Coronary Interventions.

Corindus Vascular Robotics (Corindus) has received 510(k) clearance from the FDA for its CorPath GRX, the second generation of its CorPath Vascular Robotic System. Corindus expects to commence commercialization of CorPath GRX in the first quarter of 2017. CorPath GRX builds upon the CorPath platform, adding a number of upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. These features include Active Guide Management which enables control of the guide catheter along with robotic control of the guidewire and balloon or stent catheter, with one-millimeter advancement, from the control console. This precise positioning will enable physicians to adjust guide catheter position during PCI procedures, and may expand use of CorPath to more complex cases.

CorPath GRX also features a completely redesigned Bedside Unit featuring an Extended Reach Arm and a touchscreen display to streamline workflow. Corindus' CorPath System is an FDA-cleared medical device to bring robotic precision to Percutaneous Coronary Interventions (PCI) and protects medical professionals from radiation exposure occurring in hospital cath labs.